Earlier this month, WeightWatchers made the extraordinary announcement that it would be offering its own version of the 'fat ...

The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...

Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today joined President Joe Biden in Concord, New Hampshire at the New Hampshire Technical Institute for an event on ...

The retrospective study points to fewer suicidal thoughts or attempts among adolescents taking semaglutide or liraglutide.

Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.

President Biden and Sen. Bernie Sanders (I-Vt.) will travel to New Hampshire on Tuesday to speak on health care savings ...

For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.